Research

Hormonal

Tirzepatide demonstrates greater comparative weight loss and metabolic benefits than semaglutide in real-world observational studies, particularly in patients without pre-existing diabetes.

If you are using Semaglutide and not achieving your weight loss goals, switching to Tirzepatide may result in greater weight loss and better metabolic outcomes, especially if you do not have Type 2 Diabetes. Real-world data suggests Tirzepatide is more potent than Semaglutide in routine practice.

GoodSupportsHIGH confidence
The treatment was labelled for T2D, yet only 52% of individuals in the study were classified as having T2D. The study found a larger weight loss at 12 months for tirzepatide (-15.3%) versus semaglutide (-8.3%) in individuals who had not been excluded due to discontinuation or GLP-1RA switching.
Reimar W. Thomsen et al. · Diabetes Obesity and Metabolism · 2025

Why this rating

Based on large observational cohort studies (e.g., US study of 18,000 adults), though head-to-head RCT data is still emerging.

Source

Real‐world evidence on the utilization, clinical and comparative effectiveness, and adverse effects of newer <scp>GLP</scp> ‐ <scp>1RA</scp> ‐based weight‐loss therapies

Reimar W. Thomsen et al. · Diabetes Obesity and Metabolism · 2025

DOI 10.1111/dom.16364

narrative_reviewCited 114×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →